Gastric emptying and disease activity in inflammatory bowel disease

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Gastric emptying and disease activity in inflammatory bowel disease. / Keller, Jutta; Binnewies, Ulrich; Rösch, Marie; Juul Holst, Jens; Beglinger, Christoph; Andresen, Viola; Layer, Peter.

In: European Journal of Clinical Investigation, Vol. 45, No. 12, 2015, p. 1234-42.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Keller, J, Binnewies, U, Rösch, M, Juul Holst, J, Beglinger, C, Andresen, V & Layer, P 2015, 'Gastric emptying and disease activity in inflammatory bowel disease', European Journal of Clinical Investigation, vol. 45, no. 12, pp. 1234-42. https://doi.org/10.1111/eci.12542

APA

Keller, J., Binnewies, U., Rösch, M., Juul Holst, J., Beglinger, C., Andresen, V., & Layer, P. (2015). Gastric emptying and disease activity in inflammatory bowel disease. European Journal of Clinical Investigation, 45(12), 1234-42. https://doi.org/10.1111/eci.12542

Vancouver

Keller J, Binnewies U, Rösch M, Juul Holst J, Beglinger C, Andresen V et al. Gastric emptying and disease activity in inflammatory bowel disease. European Journal of Clinical Investigation. 2015;45(12):1234-42. https://doi.org/10.1111/eci.12542

Author

Keller, Jutta ; Binnewies, Ulrich ; Rösch, Marie ; Juul Holst, Jens ; Beglinger, Christoph ; Andresen, Viola ; Layer, Peter. / Gastric emptying and disease activity in inflammatory bowel disease. In: European Journal of Clinical Investigation. 2015 ; Vol. 45, No. 12. pp. 1234-42.

Bibtex

@article{b241d43305af4f0a8222c340dc6b4cad,
title = "Gastric emptying and disease activity in inflammatory bowel disease",
abstract = "BACKGROUND: Gastric emptying (GE) is delayed in a subset of patients with inflammatory bowel disease (IBD). We have shown before that altered release of gastrointestinal hormones may contribute to GE disturbances, but overall effects of disease activity remain unclear. Thus, we aimed to evaluate GE in patients with IBD during active disease and following therapy.DESIGN: A total of 20 healthy subjects (HC) and 26 patients with IBD hospitalized because of an acute episode of their disease (Crohn's disease (CD) n = 13, ulcerative colitis (UC) n = 13) underwent a standardized (13) C-octanoic acid GE breath test (baseline test). Plasma glucose, cholecystokinin (CCK), peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) were measured periodically throughout the test. A total of 16 patients underwent a second GE test after 3-4 months of therapy.RESULTS: At baseline, nine patients with IBD had pathologically delayed GE half-time (T½ > 150 min) (P = 0·028 vs. HC). Moreover, T½ was significantly longer in the total group of patients with IBD than in HC (129 ± 12 min vs. 96 ± 7, P = 0·030). Postprandial GLP-1 responses were elevated in IBD (P = 0·002 vs. HC) and correlated with T½ (P = 0·05). Following therapy clinical activity indices and T½ were decreased in IBD (P ≤ 0·01 vs. baseline), and T½ no longer differed from HC (P > 0·5). Moreover, GLP-1 plasma levels decreased significantly (P = 0·031).CONCLUSIONS: Higher disease activity in IBD is associated with prolonged GE and increased release of GLP-1. Following effective therapy, GE is accelerated and GLP-1 release decreases significantly. Thus, increased release of GLP-1 from the inflamed mucosa might contribute to GE disturbances in IBD.",
author = "Jutta Keller and Ulrich Binnewies and Marie R{\"o}sch and {Juul Holst}, Jens and Christoph Beglinger and Viola Andresen and Peter Layer",
note = "{\circledC} 2015 Stichting European Society for Clinical Investigation Journal Foundation.",
year = "2015",
doi = "10.1111/eci.12542",
language = "English",
volume = "45",
pages = "1234--42",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Wiley-Blackwell",
number = "12",

}

RIS

TY - JOUR

T1 - Gastric emptying and disease activity in inflammatory bowel disease

AU - Keller, Jutta

AU - Binnewies, Ulrich

AU - Rösch, Marie

AU - Juul Holst, Jens

AU - Beglinger, Christoph

AU - Andresen, Viola

AU - Layer, Peter

N1 - © 2015 Stichting European Society for Clinical Investigation Journal Foundation.

PY - 2015

Y1 - 2015

N2 - BACKGROUND: Gastric emptying (GE) is delayed in a subset of patients with inflammatory bowel disease (IBD). We have shown before that altered release of gastrointestinal hormones may contribute to GE disturbances, but overall effects of disease activity remain unclear. Thus, we aimed to evaluate GE in patients with IBD during active disease and following therapy.DESIGN: A total of 20 healthy subjects (HC) and 26 patients with IBD hospitalized because of an acute episode of their disease (Crohn's disease (CD) n = 13, ulcerative colitis (UC) n = 13) underwent a standardized (13) C-octanoic acid GE breath test (baseline test). Plasma glucose, cholecystokinin (CCK), peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) were measured periodically throughout the test. A total of 16 patients underwent a second GE test after 3-4 months of therapy.RESULTS: At baseline, nine patients with IBD had pathologically delayed GE half-time (T½ > 150 min) (P = 0·028 vs. HC). Moreover, T½ was significantly longer in the total group of patients with IBD than in HC (129 ± 12 min vs. 96 ± 7, P = 0·030). Postprandial GLP-1 responses were elevated in IBD (P = 0·002 vs. HC) and correlated with T½ (P = 0·05). Following therapy clinical activity indices and T½ were decreased in IBD (P ≤ 0·01 vs. baseline), and T½ no longer differed from HC (P > 0·5). Moreover, GLP-1 plasma levels decreased significantly (P = 0·031).CONCLUSIONS: Higher disease activity in IBD is associated with prolonged GE and increased release of GLP-1. Following effective therapy, GE is accelerated and GLP-1 release decreases significantly. Thus, increased release of GLP-1 from the inflamed mucosa might contribute to GE disturbances in IBD.

AB - BACKGROUND: Gastric emptying (GE) is delayed in a subset of patients with inflammatory bowel disease (IBD). We have shown before that altered release of gastrointestinal hormones may contribute to GE disturbances, but overall effects of disease activity remain unclear. Thus, we aimed to evaluate GE in patients with IBD during active disease and following therapy.DESIGN: A total of 20 healthy subjects (HC) and 26 patients with IBD hospitalized because of an acute episode of their disease (Crohn's disease (CD) n = 13, ulcerative colitis (UC) n = 13) underwent a standardized (13) C-octanoic acid GE breath test (baseline test). Plasma glucose, cholecystokinin (CCK), peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) were measured periodically throughout the test. A total of 16 patients underwent a second GE test after 3-4 months of therapy.RESULTS: At baseline, nine patients with IBD had pathologically delayed GE half-time (T½ > 150 min) (P = 0·028 vs. HC). Moreover, T½ was significantly longer in the total group of patients with IBD than in HC (129 ± 12 min vs. 96 ± 7, P = 0·030). Postprandial GLP-1 responses were elevated in IBD (P = 0·002 vs. HC) and correlated with T½ (P = 0·05). Following therapy clinical activity indices and T½ were decreased in IBD (P ≤ 0·01 vs. baseline), and T½ no longer differed from HC (P > 0·5). Moreover, GLP-1 plasma levels decreased significantly (P = 0·031).CONCLUSIONS: Higher disease activity in IBD is associated with prolonged GE and increased release of GLP-1. Following effective therapy, GE is accelerated and GLP-1 release decreases significantly. Thus, increased release of GLP-1 from the inflamed mucosa might contribute to GE disturbances in IBD.

U2 - 10.1111/eci.12542

DO - 10.1111/eci.12542

M3 - Journal article

VL - 45

SP - 1234

EP - 1242

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 12

ER -

ID: 150707267